These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 16326808)
1. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Jin K; LaFevre-Bernt M; Sun Y; Chen S; Gafni J; Crippen D; Logvinova A; Ross CA; Greenberg DA; Ellerby LM Proc Natl Acad Sci U S A; 2005 Dec; 102(50):18189-94. PubMed ID: 16326808 [TBL] [Abstract][Full Text] [Related]
2. Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease. Kohl Z; Regensburger M; Aigner R; Kandasamy M; Winner B; Aigner L; Winkler J BMC Neurosci; 2010 Sep; 11():114. PubMed ID: 20836877 [TBL] [Abstract][Full Text] [Related]
3. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice. Ransome MI; Hannan AJ Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443 [TBL] [Abstract][Full Text] [Related]
4. Huntington's disease and neurogenesis: FGF-2 to the rescue? La Spada AR Proc Natl Acad Sci U S A; 2005 Dec; 102(50):17889-90. PubMed ID: 16330780 [No Abstract] [Full Text] [Related]
5. Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Kohl Z; Kandasamy M; Winner B; Aigner R; Gross C; Couillard-Despres S; Bogdahn U; Aigner L; Winkler J Brain Res; 2007 Jun; 1155():24-33. PubMed ID: 17512917 [TBL] [Abstract][Full Text] [Related]
6. Neurogenesis in the R6/2 mouse model of Huntington's disease is impaired at the level of NeuroD1. Fedele V; Roybon L; Nordström U; Li JY; Brundin P Neuroscience; 2011 Jan; 173():76-81. PubMed ID: 20807561 [TBL] [Abstract][Full Text] [Related]
7. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322 [TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Decressac M; Wright B; Tyers P; Gaillard A; Barker RA Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice. Rajput PS; Kharmate G; Norman M; Liu SH; Sastry BR; Brunicardi CF; Kumar U PLoS One; 2011; 6(9):e24467. PubMed ID: 21912697 [TBL] [Abstract][Full Text] [Related]
10. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Lazic SE; Grote HE; Blakemore C; Hannan AJ; van Dellen A; Phillips W; Barker RA Eur J Neurosci; 2006 Apr; 23(7):1829-38. PubMed ID: 16623840 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979 [TBL] [Abstract][Full Text] [Related]
12. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Ebert AD; Barber AE; Heins BM; Svendsen CN Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622 [TBL] [Abstract][Full Text] [Related]
14. Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Gil JM; Mohapel P; Araújo IM; Popovic N; Li JY; Brundin P; Petersén A Neurobiol Dis; 2005 Dec; 20(3):744-51. PubMed ID: 15951191 [TBL] [Abstract][Full Text] [Related]
15. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160 [TBL] [Abstract][Full Text] [Related]
16. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634 [TBL] [Abstract][Full Text] [Related]
17. NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease. Zhang H; Petit GH; Gaughwin PM; Hansen C; Ranganathan S; Zuo X; Smith R; Roybon L; Brundin P; Mobley WC; Li JY J Huntingtons Dis; 2013; 2(1):69-82. PubMed ID: 25063430 [TBL] [Abstract][Full Text] [Related]
18. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242 [TBL] [Abstract][Full Text] [Related]
19. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease. El-Akabawy G; Rattray I; Johansson SM; Gale R; Bates G; Modo M BMC Neurosci; 2012 Aug; 13():97. PubMed ID: 22876937 [TBL] [Abstract][Full Text] [Related]
20. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. Cho SR; Benraiss A; Chmielnicki E; Samdani A; Economides A; Goldman SA J Clin Invest; 2007 Oct; 117(10):2889-902. PubMed ID: 17885687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]